Microcirculatory vascular dysfunction in HIV-1 infected patients receiving highly active antiretroviral therapy

Microcirculation

Volumn 17, Issue 4, 2010, Pages 303-310

  Palios, John ^a   Ikonomidis, Ignatios ^a   Lekakis, John ^a   Tsiodras, Sotirios ^a   Poulakou, Garyfalia ^a   Antoniadou, Anastasia ^a   Panagopoulos, Periklis ^a   Papadopoulos, Antonios ^a   Giamarellou, Helen ^a   Anastasiou Nana, Maria ^a   Kremastinos, Dimitrios ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

HAART; HIV; Plethysmography; Reactive hyperemia

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE; ARTICLE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FOREARM BLOOD FLOW; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPEREMIA; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD FLOW VELOCITY; CASE-CONTROL STUDIES; FOREARM; HIV INFECTIONS; HIV-1; HUMANS; HYPEREMIA; HYPERLIPIDEMIAS; MALE; MICROCIRCULATION; MIDDLE AGED; PLETHYSMOGRAPHY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77951681957     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/j.1549-8719.2010.00023.x     Document Type: Article

References (45)

1. UNAIDS/WHO 2007). AIDS Epidemic Update the UNAIDS/WHO Annual Report. http://www.unaids.org/.
2. Palella FJ, Delaney KM, Moorman A, et al. (1998). Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 338 : 853 860.
3. Carr A, Samaras K, Burton S, et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 : F51 F58. (Pubitemid 28190689)
4. Tsiodras S, Mantzoros C, Hammer S, Samore M 2000). Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year 29 cohort study. Arch Intern Med 160 : 2050 2056. (Pubitemid 30437589)
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA 1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 353 : 2093 2099. (Pubitemid 29278477)
6. Stein JH, Klein MA, Bellehumeur JL, et al. (2001). Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104 : 257 262.
7. Depairon M, Chessex S, Sudre P, et al. (2001). Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 15 : 329 334. (Pubitemid 32163818)
8. Henry K, Melroe H, Huebsch J, et al. (1998). Severe premature coronary artery disease with protease inhibitors. Lancet 351 : 1328. (Pubitemid 28195913)
9. Grinspoom S, Carr A 2003). Cardiovascular risk and body fat abnormalities in HIV infected adults. New Engl J Med 349 : 48 62.
10. Walli R, Herfort O, Michi GM, et al. (1998). Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV patients. AIDS 12 : 163 167. (Pubitemid 28479266)
11. Periard D, Telenti A, Sudre P, et al. (1999). Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100 : 700 705. (Pubitemid 29383638)
12. Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S 2003). Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? Q J Med 96 : 825 832. (Pubitemid 37369296)
13. Blum A, Hadas V, Burke M, Yust I, Kessler A 2005). Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol 28 : 149 153. (Pubitemid 40364508)
14. de Saint Martin L, Vandhuick O, Guillo P, et al. (2006). Premature atherosclerosis in HIV infected patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 185 (2) : 361 367. (Pubitemid 43306750)
15. Jerico C, Knobel H, Calvo N, et al. (2006). Subclinical carotid atherosclerosis in HIV infected patients. Role of combination antiretroviral therapy. Stroke 37 : 812 817. (Pubitemid 43731914)
16. Holmberg SD, Moorman AC, Williamson JM, et al. (2002). Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 : 1747 1748. (Pubitemid 35447907)
17. DAD Study Group 2003). Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 : 1991 2003.
18. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA 2003). Cardiovascular and cerebrovascular events in patients treated for HIV infection. N Engl J Med 348 : 702 710.
19. Lekakis J, Tsiodras S, Ikonomidis I, et al. (2008). HIV positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clin Sci 115 : 189 196.
20. Lekakis J, Ikonomidis I, Palios J, et al. (2009). Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus. Am J Hypertens 22 : 828 834.
21. Thijssen DH, Bleeker MW, Smits P, Hopman MT 2005). Reproducibility of blood flow and post-occlusive reactive hyperemia as measured by venous occlusion plethysmograrhy. Clin Sci (Lond) 108 (2) : 151 157. (Pubitemid 40175409)
22. Tonari S, Nishimura H, Fukunishi K, Mori T, Kitaura Y 2003). Forearm hyperemia is a better marker than carotid intima-media thickness or ankle-brachial index for coronary artery disease in Japanese males under 65. Hypertens Res 26 : 59 65. (Pubitemid 36193100)
23. Gamble J, Gartside IB, Christ F 1993). A reassessment of mercury in silastic strain gauge plethysmography for microvascular permeability assessment in man. J Physiol (Lond) 464 : 407 422. (Pubitemid 23169323)
24. Jaap AJ, Shore AC, Gartside IB, Gamble J, Tooke JE 1993). Increased microvascular fluid permeability in young type 1 diabetic patients. Diabetologia 36 : 648 652.
25. Tousoulis D, Antoniades C, Bosinakou E, et al. (2005). Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178 : 359 363. (Pubitemid 40193452)
26. Ouchi N, Ohishi M, Kihara S, et al. (2003). Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42 : 231 234. (Pubitemid 37093465)
27. Perticone F, Ceravolo R, Pujia A, et al. (2001). Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104 : 191 196. (Pubitemid 32655837)
28. Fichtlscherer S, Breuer S, Zeiher A 2004). Prognostic value of systematic endothelial dysfunction in patients with acute coronary syndromes. Circulation 110 : 1926 1932.
29. Ishibashi Y, Duncker DJ, Zhan GJ 1998). ATP-sensitive K+ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise. Circ Res 82 : 346 359. (Pubitemid 28101192)
30. Bijlstra PJ, Den Arend CACJ, Lutterman JA 1996). Blockade of vascular ATP-sensitive potassium channels reduces the vasodilator response to ischaemia in adults. Diabetologia 39 : 1562 1568.
31. Rui-Juan X, Cheng J, Berglund O 1991). Microcirculatory disturbances in AIDS patients. Microvasc Res 42 : 151 159.
32. Monsuez JJ, Dufaux J, Vittecoq D, Vicaut E 2000). Reduced reactive hyperemia in HIV- infected patients. J Acquir Immune Defic Syndr 25 : 434 442. (Pubitemid 32055573)
33. Hammer SM, Saag MS, Schechter M, et al. (2006). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 : 827 843. (Pubitemid 44223106)
34. Dressman J, Kincer J, Matveev SV, et al. (2003). HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD-36 dependent cholesterol accumulation in macrophages. J Clin Invest 111 : 389 397. (Pubitemid 36182216)
35. Paton P, Tabib A, Loire R, Tete R 1993). Coronary artery lesions and HIV infection. Res Virol 144 : 225 231.
36. Lewis W 2005). Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy. Antivir Ther 10 (Suppl 2 M13 M27. (Pubitemid 41224938)
37. Conklin BS, Fu W, Lin PH, Lumsden AB, Yao Q, Chen C 2004). HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiovasc Res 63 : 168 175. (Pubitemid 38759822)
38. Zhong DS, Lu XH, Conklin BS, et al. (2002). HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 22 : 1560 1566.
39. Monsuez J, Charniot J, Escaut L, et al. (2009). HIV-associated vascular diseases: structural and functional changes, clinical implications. Int J Cardiol 133 : 293 306.
40. Zangerle R, Fuchs D 2008). Increased cardiovascular risk in patients with human immunodeficiency virus infection under highly active antiretroviral therapy. Am J Cardiol 102 : 373 374.
41. Hoffmann G, Kenn S, Wirleitner B, et al. (1998). Neopterin induces nitric oxide-dependent apoptosis in rat vascular smooth muscle cells. Immunobiology 199 : 63 73. (Pubitemid 28345004)
42. Eugenin EA, Morgello S, Klotman ME 2008). Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 172 : 1100 1111. (Pubitemid 351520006)
43. Strano S, masseti A, Mastroianni CM, Vullo V 2009). Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment. Atherosclerosis 204 : e1 e3.
44. Lima EM, Gualandro DM, Yu PC, et al. (2009). Cardiovascular prevention in HIV patients: results from a successful intervention program. Atherosclerosis 204 (1) : 229 232.
45. De Lorenzo F, Boffito M, Collot-Teixeira S, et al. (2009). Prevention of atherosclerosis in patients living with HIV. Vasc Health Risk Manag 5 (1) : 287 300.